Do interleukin-17 and interleukin-23 inhibitors alter the coagulation parameters in psoriasis patients?: A retrospective study.
Coagulation parameters
IL-17 inhibitors
IL-23 inhibitors
MACE
Prothrombin time
Psoriasis
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
received:
05
08
2024
accepted:
03
09
2024
revised:
23
08
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
epublish
Résumé
Psoriasis is a chronic inflammatory skin condition associated with systemic inflammation and a higher risk of cardiovascular comorbidities. This study retrospectively evaluates coagulation parameters in psoriasis vulgaris patients treated with IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (risankizumab, guselkumab), compared to those untreated systemically. The study reviewed records from 177 patients treated between January 2019 and March 2023. Patients were grouped into control (n = 77), secukinumab (n = 36), ixekizumab (n = 19), guselkumab (n = 24), and risankizumab (n = 21). Coagulation parameters, including PT, aPTT, PLT, MPV, INR, fibrinogen, D-dimer, and B12 levels, were analyzed. The primary endpoint was the comparison of coagulation parameters between groups. Significant differences were found in PT, with secukinumab-treated patients showing a significantly shorter PT compared to controls (p = 0.002). No significant differences were observed in other coagulation parameters across the groups. The study highlights a potential effect of secukinumab on coagulation pathways, possibly related to IL-17's role in inflammation and endothelial function. Despite current literature suggest a risk of cerebrovascular events with risankizumab, this study did not show any significant changes in coagulation parameters with risankizumab, indicating no hypercoagulability risk associated with this IL-23 inhibitor. Our findings suggest IL-17 and IL-23 inhibitors are generally safe concerning coagulation parameters, but regular monitoring may be warranted for patients on secukinumab due to its effect on PT. Further long-term studies are needed to fully understand the cardiovascular risks associated with these therapies.
Identifiants
pubmed: 39259347
doi: 10.1007/s00403-024-03369-3
pii: 10.1007/s00403-024-03369-3
doi:
Substances chimiques
Interleukin-17
0
Antibodies, Monoclonal, Humanized
0
Interleukin-23
0
secukinumab
DLG4EML025
ixekizumab
BTY153760O
risankizumab
90ZX3Q3FR7
guselkumab
089658A12D
Antibodies, Monoclonal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
613Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM (2020) National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 369:m1590
doi: 10.1136/bmj.m1590
pubmed: 32467098
pmcid: 7254147
Boehncke W-H (2018) Systemic inflammation and Cardiovascular Comorbidity in Psoriasis patients: causes and consequences. Front Immunol 9:579
doi: 10.3389/fimmu.2018.00579
pubmed: 29675020
pmcid: 5895645
Bai F, Li GG, Liu Q, Niu X, Li R, Ma H (2019) Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and Networ. J Immunol Res 2019:2546161
doi: 10.1155/2019/2546161
pubmed: 31583255
pmcid: 6754904
Visser MJE, Tarr G, Pretorius E (2021) Thrombosis in Psoriasis: cutaneous cytokine production as a potential Driving Force of Haemostatic Dysregulation and subsequent Cardiovascular risk. Front Immunol 12:688861
doi: 10.3389/fimmu.2021.688861
pubmed: 34335591
pmcid: 8324086
Mir MM, Dogra D, Koul KK (2022) Hemostatic and Coagulation Profile in Psoriasis: A Hospital-based case control study. Indian J Dermatol 67(3):247–251
doi: 10.4103/ijd.IJD_630_20
pubmed: 36386096
pmcid: 9644789
Woods RH (2023) Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA adverse event reporting System (FAERS). Br J Clin Pharmacol 89(8):2386–2395
doi: 10.1111/bcp.15581
pubmed: 36321844
Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y (2008) Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm Venereol 88(4):337–340
doi: 10.2340/00015555-0456
pubmed: 18709301
Chandrashekar L, Rajappa M, Revathy G, Sundar I, Munisamy M, Ananthanarayanan PH et al (2015) Is enhanced platelet activation the missing link leading to increased cardiovascular risk in psoriasis? Clin Chim Acta 446:181–185
doi: 10.1016/j.cca.2015.04.023
pubmed: 25920693
Conic RRZ, Damiani G, Schrom KP, Ramser AE, Zheng C, Xu R et al (2020) Psoriasis and psoriatic arthritis cardiovascular disease endotypes identified by red blood cell distribution width and mean platelet volume. J Clin Med. ;9(1)
Esen M (2024) The effect of IL17 and IL23 inhibitors on hematological parameters and C-reactive protein in psoriasis patients. Cutan Ocul Toxicol 43(1):38–45
doi: 10.1080/15569527.2023.2275020
pubmed: 37897439
Ataseven A, Temiz SA, Eren G, Özer İ, Dursun R (2022) Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics. J Dermatolog Treat 33(2):1091–1096
doi: 10.1080/09546634.2020.1801975
pubmed: 32713225
Park Y, Shim Y, Kwon I, Lee HW, Nam HS, Choi H-J et al (2022) Effects of Interleukin-17A on the early stages of arterial thrombosis in mice. Yonsei Med J 63(7):632–639
doi: 10.3349/ymj.2022.63.7.632
pubmed: 35748074
pmcid: 9226831
Gidaro A, Delitala AP, Manetti R, Caccia S, Soloski MJ, Lambertenghi Deliliers G et al (2023) Platelet microvesicles, inflammation, and coagulation markers: a pilot study. Hematol Rep 15(4):684–695
doi: 10.3390/hematolrep15040069
pubmed: 38132277
pmcid: 10742513
von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A et al (2019) Impact of Secukinumab on endothelial dysfunction and other Cardiovascular Disease parameters in Psoriasis patients over 52 weeks. J Invest Dermatol 139(5):1054–1062
doi: 10.1016/j.jid.2018.10.042
Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM (2017) Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 176(4):890–901
doi: 10.1111/bjd.14964
pubmed: 27518205
pmcid: 5412670
Campello E, Spiezia L, Zabeo E, Maggiolo S, Vettor R, Simioni P (2015) Hypercoagulability detected by whole blood thromboelastometry (ROTEM
doi: 10.1016/j.thromres.2015.01.003
pubmed: 25592651
Egeberg A, Thyssen JP (2023) Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration adverse events reporting System (FAERS). Br J Dermatol 188(6):793–794
doi: 10.1093/bjd/ljad039
pubmed: 36797979
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A et al (2024) Effectiveness, tolerability, and Drug Survival of Risankizumab in a Real-World setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Clin Med. ;13(2)
Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG et al (2022) Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 186(3):466–475
doi: 10.1111/bjd.20818
pubmed: 34652810
Mattay SS, Zamani M, Saturno D, Loftus EVJ, Ciorba MA, Yarur A et al (2023) Risk of major adverse Cardiovascular events in Immune-mediated inflammatory disorders on Biologics and Small molecules: Network Meta-Analysis. Clin Gastroenterol Hepatol off Clin Pract J Am Gastroenterol Assoc
Ding L, Chen C, Yang Y, Zhang X (2024) Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data. Front Immunol 15(February):1–11
Egeberg A, Skov L, Joshi AA, Mallbris L, Gislason GH, Wu JJ et al (2017) The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol 77(4):650–656e3
doi: 10.1016/j.jaad.2017.06.028
pubmed: 28826925
pmcid: 5657544